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Figure S1. ZIKV mutations in Ifnar1-/- mice. Related to Figure 1. 
Summary of the analysis of ZIKV EDIII sequences from infected mouse blood at the indicated time points. 
Empty cells represent sequences not determined, yellow cells are samples from symptomatic mice, wt is 
wild type EDIII sequence. The only identified mutation (K394R, in red) was in a mouse pre-treated with 
Z004.  
 
 
 
  
 
 
 
 
 
 
Figure S2. Human IgG levels in macaque plasma over time. Related to Figure 4. 
The levels of human IgG antibodies were determined by ELISA. The left panel displays human IgGs in 
individual macaques, the right panel shows the mean for each group. Macaques were administered 
15mg/kg of each of the antibodies on day -1. The mean peak antibody levels on the day of infection (day 0) 
were 334 µg/ml in the Z004 + Z021 group and 326 µg/ml in the Z004-GRLR + Z021-GRLR group. The 
antibody levels on day 15 were 32 µg/ml in the Z004 + Z021 group and 34 µg/ml in the Z004-GRLR + 
Z021-GRLR group, resulting in plasma half-lives of 4.4 and 4.6 days, respectively. 
 
 
 Figure S3. Z004 containing mutations in the antibody Fc portion that prevent Fcγ  receptor binding 
(GRLR)(Horton et al., 2008; Lu et al., 2016) and extend the half-life (LS)(Ko et al., 2014; Zalevsky et 
al., 2010) remains effective against ZIKV. Related to Figure 4. 
(A) Z004-mediated ADE of Fcγ receptor bearing K-562 cells is abrogated by GRLR and GRLR/LS 
substitutions. Data are represented as mean ± SD of triplicates. The positive control (+) is wild type Z004 
antibody (10 ng/ml).  
(B) Surface plasmon resonance (SPR) binding profile of Z004 bearing the LS and GRLR mutations alone 
or in combination.  
(C-D) Z004 antibodies bearing the LS and GRLR substitutions alone or in combination remain effective 
against ZIKV RVPs in vitro (C) or ZIKV in vivo following prophylactic administration (D). 
 Figure S4. Z021 with substitutions that prevent Fcγ  receptor binding (GRLR) and extend the half-
life (LS) remains effective against ZIKV. Related to Figure 4. 
(A) Z021-mediated ADE is abrogated by GRLR and GRLR/LS substitutions. Data are represented as mean 
± SD of triplicates. The positive control (+) is wild type Z004 antibody (10 ng/ml).  
(B-C) Z021 antibodies bearing the LS and GRLR substitutions remain effective against ZIKV RVPs in 
vitro (B) or ZIKV in vivo following prophylactic administration (C). 
(D) K294R arising in macaque 6171 is not a virus escape mutation. On top is the location of the K294 
residue on the structure of the sE dimer of ZIKV (PDB ID: 5JHM). The structures of the Z004-related 
antibody Z006 and of Z021 in complex with the EDIII of ZIKV are structurally aligned to the sE dimer to 
show the location of K294 relative to the binding sites of the antibodies. The ZIKV EDIII from the Z006-
EDIII and Z021-EDIII structures are omitted for clarity. At the bottom, Z004 and Z021 similarly neutralize 
wild type (left) and K294R mutant (right) ZIKV RVPs. Data are represented as mean ± SD of triplicates 
and a representative of two experiments is plotted. Values are relative to no antibody control. 
 
Table S1- Structural statistics for Z021 bound to ZIKV EDIII and DENV1 EDIII. Related to Figure 
3.  
Statistics for the highest-resolution shell are shown in parentheses. 
 
 
 	
  Z021-ZIKV EDIII Z021–DENV1 EDIII 
Data Collection   
Resolution Range (Å) 75.25 - 2.48 (2.57 - 2.48) 50.51 - 2.07 (2.13  - 2.07) 
Space group P212121 C 2 2 21 
Cell dimensions   
       a, b, c (Å) 73.89, 105.62, 107.24 60.54, 91.60, 187.14 
      α, β, γ (º) 90, 90, 90 90, 90, 90 
Total reflections 111776 (12819) 185501 (14638) 
Unique reflections 30524 (3427) 31907 (2463) 
Multiplicity 3.7 (3.7) 5.8 (5.9) 
Completeness (%) 99.7 (99.9) 99.7 (99.9) 
Mean I/σ(I) 7.8 (2.2) 15.0 (2.3) 
Wilson B-factor (Å2) 44.52 50.34 
Rmerge 0.091 (0.486) 0.046 (0.702) 
Rpim 0.077 (0.418) 0.030 (0.461) 
CC1/2 0.993 (0.696) 0.997 (0.724) 
   
Refinement   
Rwork/Rfree 18.2% / 22.8% 18.4% / 23.2% 
Number of atoms 4163 4191 
Protein atoms 4095 4065 
Solvent atoms 68 126 
Protein residues 537 532 
RMS (bonds) (Å) 0.008 0.006 
RMS (angles) (˚) 1.22 1.12 
Clashscore 2.97 3.85 
Average B-factor (Å2) 48.71 67.96 
Number of TLS groups 5 5 	
 
 
 
 
 
Table S2- Contact residues between Z021 and ZIKV EDIII and Z021 and DENV1 EDIII. Related to 
Figure 3. 
Contacts are defined as residues in which any atom is within 4 Å of an atom from a residue on the 
interacting partner using AntibodyDatabase (West et al., 2013). The table is organized by antibody residue, 
listing all antigen residues contacted by each antibody residue. Asterisk (*) indicates that experimental 
density for side chain is not present and therefore side chain position cannot be accurately modeled. It is 
unlikely that these residues are actually involved in binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. List of primers used in this study. Related to STAR Methods. 
 
 
 
 
Primer ID Primer sequence Comments 
Mutagenesis of IGγ1 expression vector to produce GRLR and LS Fc mutant antibodies 
DFRp1455 TGAACTCCTGAGGGGACCGTCAGTC For G236R in GRLR mutant 
DFRp1456 GGTGCTGGGCACGGTGGG For G236R in GRLR mutant 
DFRp1457 AACAAAGCCCGCCCAGCCCCC For L328R in GRLR mutant 
DFRp1458 GGAGACCTTGCACTTGTACTCCTTG For L328R in GRLR mutant 
DFRp1459 ATGCTCCGTGCTGCATGAGGC For M428L in LS mutant 
DFRp1460 GAGAAGACGTTCCCCTGC For M428L in LS mutant 
DFRp1461 GCTCTGCACAGCCACTACACG For N434S in LS mutant 
DFRp1462 CTCATGCAGCACGGAGCATG For N434S in LS mutant 
Mutagenesis of ZIKV EDIII expression vector to produce mutant EDIII proteins 
E393A/K394A TTGTCATAGGAGTCGGGGCGGCGAAGATCACCCACCACT
G 
For E393A/K394A mutant  
E393D CATAGGAGTCGGGGACAAGAAGATCACCCAC For E393D mutant  
K394R GTCATAGGAGTCGGGGAGCGTAAGATCACCCACCACTGG For K394R mutant  
Mutagenesis of pZIKV/HPF/CprM*E* to produce mutant ZIKV RVPs 
RU-O-24379 ACTTGGTCATGATACTGCTGATTGCCCCGGCATACAGCAT
CAGGTGCATAGGAGT 
Forward outer 
RU-O-24380 TTCGAACCGCGGCTGGGTCCTATTAAGCAGAGACAGCTG
TGGATAAGAAGATC 
Reverse outer 
RU-O-25002 AGGAGTCGGGGCGGCGAAGATCACCCAC Forward E393A/K394A 
RU-O-25003 GTGGGTGATCTTCGCCGCCCCGACTCCT Reverse E393A/K394A 
DFRp1500 AAATGTCGCCTGAGAATGGATAAACTTAGATTG Forward K294R 
DFRp1501 TCTAAGTTTATCCATTCTCAGGCGACATTTCAA Reverse K294R 
Primers to amplify and sequence the ZIKV EDIII region 
1618p ACAAGGAGTGGTTCCATGACA First set (macaque) 
2204n TTTTCCGATGGTGCTGCCAC First set (macaque) 
1970p GTATGCAGGGACAGATGGACC Second set (macaque) 
2537n ACCGCATCTCGTTTCCTTCTT Second set (macaque) 
DFRp1284 GGATGATCGTTAATGACACAG First PCR (mouse) 
DFRp1469 ACCATCTTCCCAGGCTTG First PCR (mouse) 
DFRp1283 GGATCCTGATTTGAAAGCTGC Sequencing primer (mouse) 
DFRp1472 TTCCACGACATTCCATTACC Nested PCR (mouse) 
DFRp1470 ATCTACGGGGGGAGTCAGGATG Nested PCR (mouse) 
 
